Table of contents
- Latest Ditropan Lawsuit Updates
- November 12, 2024: BMJ Medicine Study Tests Bladder Drugs
- May 4, 2023: AGS Publishes Updated Beers Criteria
- September 6, 2022: SUFU Publishes White Paper on Dementia Risk
- April 25, 2018: BMJ Publishes Case-Control Study
- What Is Ditropan?
- Who May Be Affected?
- Reported Injuries or Damages
- Evidence to Preserve
- Filing Deadlines
- Frequently Asked Questions
- Is Ditropan Associated with Dementia?
- Who Should Not Take Ditropan?
- Are Oxybutynin and Ditropan the Same Drug?
- Is Oxybutynin a High-Risk Medication for Older Adults?
- Should I Stop Taking Ditropan Now?
- What Does the Research Say About Short-Term Use of Ditropan?
Studies report that long-term use of anticholinergic bladder drugs is associated with a higher risk of dementia in older adults. Oxybutynin, a bladder drug sold as Ditropan, is one of the drugs studied.
No filed case, MDL or class action names Ditropan and dementia. The concern so far comes from medical studies and guidelines, not from a court.
These studies show an association, not proof that the drug caused dementia. Generic oxybutynin may still be available, because the Ditropan brand is no longer on the market.
Latest Ditropan Lawsuit Updates
November 12, 2024: BMJ Medicine Study Tests Bladder Drugs
BMJ Medicine published a nested case-control study of anticholinergic bladder drugs and dementia in adults aged 55 and older [1]. For oxybutynin hydrochloride, the adjusted odds ratio was 1.31 (95% CI 1.21 to 1.42).
The authors found that oxybutynin, solifenacin and tolterodine were most strongly associated with dementia risk in older adults. Its data covered 15 418 patients with dementia and 63 369 controls.
May 4, 2023: AGS Publishes Updated Beers Criteria
The American Geriatrics Society published its 2023 updated Beers Criteria online [2]. The list names medicines that are typically best avoided by older adults.
September 6, 2022: SUFU Publishes White Paper on Dementia Risk
The SUFU urology society published a white paper online [3]. It says chronic use, over 3 months, of overactive bladder anticholinergics is likely associated with an increased risk of new-onset dementia.
The paper rests on an expert literature review and committee opinion. It appeared in the journal Neurourology and Urodynamics and reviewed overactive bladder anticholinergic medications.
April 25, 2018: BMJ Publishes Case-Control Study
The 2018 BMJ study was a case-control study of anticholinergic drugs and dementia in UK general practices [4]. It reported a robust association between some classes of anticholinergic drugs and later dementia.
The authors said this could be a class-specific effect. It could also reflect drugs used for very early symptoms of undiagnosed dementia. BMJ later added a correction dated October 31, 2019.
What Is Ditropan?
According to MedlinePlus, oxybutynin treats overactive bladder and helps control bladder muscles weakened in certain nerve conditions [5]. It is in a class of medicines called anticholinergics. It works by relaxing the bladder muscles.
Ditropan and Ditropan XL are brand names of this drug. The studies on this page look at oxybutynin and related bladder drugs, not only the Ditropan brand.
Who May Be Affected?
Adults prescribed oxybutynin for overactive bladder, as Ditropan, Ditropan XL or a generic, are the people the studies cover. The BMJ Medicine study looked at adults aged 55 and older. The Beers Criteria apply to adults 65 and older.
The BMJ Medicine odds ratios apply at 366 to 1095 and over 1095 total standardised daily doses, among people who later had a dementia diagnosis.
Whether a claim exists depends on your own facts and an individual legal review, and people with the same prescription can have different circumstances.
Reported Injuries or Damages
No complaint alleges an injury from Ditropan. The concern is dementia. It comes from studies that report an association with dementia and cannot prove what caused it.
The Ditropan XL label lists anticholinergic central nervous system effects “including hallucinations, agitation, confusion and somnolence” [6]. Its adverse reactions include confusional state and memory impairment.
The label advises caution in patients with preexisting dementia treated with cholinesterase inhibitors “due to the risk of aggravation of symptoms”. These are label statements, not allegations.
A JAMA Internal Medicine cohort study followed 3434 participants aged 65 and older [7]. Higher cumulative anticholinergic use was associated with increased dementia risk.
The adjusted hazard ratio was 1.54 (95% CI 1.21-1.96) above 1095 total standardised daily doses. In BMJ Medicine, the oxybutynin odds ratio was 1.28 (1.15 to 1.43) above 1095 doses.
Evidence to Preserve
Keep any records that show what you took, when you took it and what changed afterward:
- Prescription and pharmacy records showing the drug, strength and dates
- The names of the prescriber and the pharmacy
- Medical records with any cognitive or memory diagnosis and its date
- A current medication list
- Photos of pill bottles or packaging
- Notes on symptoms and who observed them
Filing Deadlines
Filing deadlines come from state law. They vary with where you live and when the injury and the diagnosis happened.
Some states start the clock at diagnosis. Once a deadline passes, a claim for a Ditropan injury may be barred, however strong the facts seem.
Talk with a lawyer promptly so you know which deadline may apply to your situation and how much time may be left.
Frequently Asked Questions
Is Ditropan Associated with Dementia?
Oxybutynin, sold as Ditropan, is associated with dementia in observational studies. In BMJ Medicine, any overactive bladder anticholinergic had an adjusted odds ratio of 1.18, and the median age of the patients was 83.
Who Should Not Take Ditropan?
Patients who should not take Ditropan include those with urinary retention, gastric retention, other severe decreased gut motility, uncontrolled narrow-angle glaucoma, and hypersensitivity to the drug or its components, according to the label for the extended-release tablet.
Are Oxybutynin and Ditropan the Same Drug?
Yes, oxybutynin and Ditropan are the same drug. MedlinePlus, last revised 09/15/2025, says the branded product is no longer on the market. It adds that generic alternatives may be available.
Is Oxybutynin a High-Risk Medication for Older Adults?
Oxybutynin is not usually advised for older adults, MedlinePlus says, because the tablets and syrup are not as safe and may not work as well as other medicines used to treat the same condition.
Should I Stop Taking Ditropan Now?
Whether to stop taking Ditropan is a question for your doctor. MedlinePlus says not to stop taking oxybutynin without talking to your doctor. The Ditropan XL label says that if anticholinergic central nervous system effects occur, dose reduction or drug discontinuation should be considered.
What Does the Research Say About Short-Term Use of Ditropan?
The research on short-term use of Ditropan covers the drug class. The SUFU white paper states that short-term use, under 4 weeks, of most overactive bladder anticholinergic medications is likely safe in most individuals.